NVX-CoV2373 is a protein subunit vaccine for Covid-19 from Novavax. It was the first protein sub-unit vaccine to be approved in Europe or the USA.

NVX-CoV2373 is engineered from the genetic sequence of the first strain of SARS-CoV-2. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate.

Novavax' COVID-19 vaccine is packaged as a liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius.

Marketing Name: Nuvaxovid, CovoVax (in India, Indonesia)

Funded, in part, by Operation Warp Speed (OWS).

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice¹⁾

Clinical Trial Phase I/II: Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine²⁾

Clinical Trial Phase III: PREVENT-19: Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine (North and South America)in NEJM³⁾ and factsheet⁴⁾
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine (UK) ⁵⁾

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant⁶⁾

November 1, 2021: Indonesia⁷⁾
November 17, 2021: Philippines⁸⁾
December 17, 2021: World Health Organization (WHO) granted Emergency Use Listing for Covovax.⁹⁾
December 20, 2021: EMA granted conditional marketing authorization.¹⁰⁾
February 3, 2022: UK granted EUA.¹¹⁾
December 28, 2021: The Drugs Controller General of India (DCGI) has issued Emergency Use Authorization (EUA) for Covovax /Recombinant Spike Protein of SARS-CoV-2 Virus 5 mcg to induce immunity against SARS-CoV-2 to prevent COVID-19 for adults 18 years old and above.¹²⁾